Profile: Impax Laboratories Inc (IPXL.O)
17 Apr 2015
Impax Laboratories, Inc., incorporated on March 23, 1995, is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
The Company is focused on developing, manufacturing, selling and distributing controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. The Company employs its technologies and formulation to develop generic products, which reproduce brand name products’ physiological characteristics. It also develops, manufactures, sells and distributes specialty generic pharmaceuticals. The Company sells and distributes generic pharmaceutical products through four sales channels: the Global Product sales channel, which include generic pharmaceutical prescription products it sells directly to wholesalers, retail drug chains, and others; the Rx Partner sales channel, which include generic prescription products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements; the Private Label sales channel, which include generic pharmaceutical over the counter (OTC) and prescription products it sells to unrelated third parties who in-turn sell the product under their own label, and the OTC Partner sales channel, which include sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities pursuant to alliance and collaboration agreements. As of February 6, 2015, it marketed 96 generic pharmaceutical products representing dosage variations of 29 different pharmaceutical compounds through its Impax Generics, and five other generic pharmaceutical products, representing dosage variations of two different pharmaceutical compounds, through its alliance and collaboration agreement partners.
Impax Specialty Pharma
The Impax Specialty Pharma is focused on the development and promotion through its specialty sales force of branded pharmaceutical products for the treatment of CNS disorders, which include migraine, multiple sclerosis, Parkinson’s disease and postherpetic neuralgia. The Company’s branded pharmaceutical product portfolio consists of commercial CNS products and development stage projects. The Company has an internally developed branded pharmaceutical product, RYTARY (IPX066) for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and/or manganese intoxication. RYTARY is an extended release oral capsule formulation of CD-LD, which is intended to maintain consistent plasma concentration of levodopa for a longer duration.
The Company competes with Teva Pharmaceutical Industries Ltd., Actavis plc., Mylan Inc., Ranbaxy Laboratories Ltd., Lannett Company, Inc., Lupin Pharmaceuticals, Inc., Par Pharmaceutical Companies, Inc. and Sandoz.
Impax Laboratories Inc
30831 Huntwood Ave
HAYWARD CA 94544-7003